INTRODUCTION
Secukinumab (SEK), a fully human antie interleukin (IL)-17A monoclonal antibody, is effective in the treatment of psoriasis. Although it has a favorable safety profile, 2 cases of associated oral lichen planus (OLP)/lichenoid mucositis have been recently described.
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CASE REPORT
A 45-year-old man with severe chronic plaque psoriasis was first seen in May 2006. Associated diseases included diabetes, dyslipidemia, chronic liver disease, and pancreatitis. He received unsuccessful treatments with acitretin, psoralen and ultraviolet A, ciclosporin, methotrexate, infliximab, ustekinumab, adalimumab, etanercept, and golimumab. In December 2015, SEK treatment at standard doses was started. After a good initial response, the effectiveness decreased progressively. After 8 months, the patient had painful ulcerative lesions surrounded by a whitish discoloration of the mucosa on both sides and the back of the tongue (Fig 1) . There was no history of injuries, dental procedures, any oral disease, or new drug use. Culture from the ulcers was positive for Candida albicans and negative for herpes simplex virus. A microarray study of the ulcers was positive for Epstein-Barr virus (EBV). Two biopsies found ulcerative lichenoid mucositis with scarce pseudohyphae on the surface (Fig 2) . Direct immunofluorescence was negative. Immunohistochemical study in the biopsy tissue was negative for both EBV latent membrane protein 1 and EBV-encoded small RNA. Amplification of EBV DNA by real-time polymerase chain reaction was undetectable in peripheral blood. Serum antiedesmoglein-1 and -3, anti-BP180 and anti-BP230 antibodies were not detected. The patient was treated with intralesional corticosteroids and oral itraconazole. The lesions improved but persisted. After 12 months, SEK was discontinued and changed to apremilast. After a short course of treatment, psoriasis remained refractory, although ulcerative oral lesions clearly improved and completely disappeared 8 weeks after SEK withdrawal.
Finally, the patient was treated with the humanized antieIL-17A monoclonal antibody, ixekizumab, achieving clearance of psoriasis. After 1 month, the patient had whitish plaques but not ulcers. Biopsy and cultures found oral candidiasis without lichenoid inflammation. The lesions resolved with fluconazole, and there was no recurrence during the last 9 months with ixekizumab.
DISCUSSION
Two psoriatic patients with oral lesions presumably induced by SEK have been described. The first patient had an ulcerative lichenoid mucositis on the lower lip a few days after starting treatment. The lesions were considered a possible antieIL-17 drugrelated class effect presenting as a lichenoid drug eruption rather than a true OLP. SEK discontinuation led to improvement of the lesions. 1 The second patient had a painful whitish plaque on the buccal mucosa 5 months after SEK. In this case, an OLP associated with candidiasis was diagnosed. 2 Although the etiology of OLP remains uncertain, sometimes viral and Candida infections have been reported associated with its development. 3 Similarly, some drugs, including tumor necrosis factorea inhibitors, have been associated with the induction of oral lichen planuslike reactions. 4 In addition, Candida infections are a well-known consequence of impaired IL-17 immunity 5, 6 and therefore a moderately frequent adverse effect of IL-17 inhibitors. In our patient, the clinical and histopathologic characteristics of the lesions led us to consider the diagnosis of lichenoid inflammation, although we are unable to determine whether they represent a true OLP or a lichenoid eruption. The chronological association with the initiation of SEK, the persistence of the lesions throughout the therapy, the complete healing of the ulcers after SEK discontinuation, and the absence of other causes that could justify the lesions, suggest an etiologic role of SEK in their development. Although it cannot be ruled out, we consider unlikely that either C albicans or EBV play a role. The fact that the ulcerative lesions did not appear during treatment with ixekizumab supports that they may be a drug-related, rather than a classrelated adverse event. 
